Objective: To estimate the cost-effectiveness of anorectal chlamydia screening among men who have sex with men (MSM) in care at HIV treatment centers. Design: Transmission model combined with economic analysis over a 20-year period.
Introduction
In most industrialized countries, men who have sex with men (MSM) comprise the majority of persons with incident HIV infections [1, 2] . Routine screening for sexually transmitted infections (STI) among those in care at HIV treatment centers may substantially lower the STI incidence in the MSM population [3] . It may also lower HIV incidence, on the hypotheses that STI infection in an HIV-positive person increases HIV transmissibility, and STI in an HIV-negative person increases susceptibility to HIV infection [4] [5] [6] [7] [8] . The STI guidelines of the US Centers for Disease Control and Prevention recommend at least annual STI screening for MSM, and even more frequent screening for high-risk MSM (i.e. at 3-6 month intervals) [9] . Some countries follow these guidelines and have implemented STI screening at HIV treatment centers. In the Netherlands and other countries, STI screening is separated from HIV care, and many MSM are not screened because they do not attend an STI clinic, general practitioner (GP) or dermatologist on their own initiative, unless STI symptoms are present. No studies have been published that investigate the cost-effectiveness of adding STI screening to HIV care. The resulting lack of insight may present a barrier for countries considering the feasibility of an integrated program.
The high prevalence of asymptomatic STI among MSM [10] motivated us to explore the effectiveness and cost-effectiveness of routine STI screening among MSM in care at HIV treatment centers. We constructed a transmission model, which was combined with an economic analysis. As the complexity of the model forced us to focus on one STI, we studied asymptomatic anorectal Chlamydia trachomatis, the most prevalent STI among HIV-infected MSM with no STI symptoms in the Netherlands [10] .
Methods
We developed a model of the sexual transmission of HIV and anorectal Chlamydia trachomatis (hereinafter, chlamydia) in MSM to assess the effectiveness of routine chlamydia screening. In the model, the sexual transmission of HIV or chlamydia occurs only via unprotected anal intercourse (UAI). This model was combined with an economic model to estimate the cost-effectiveness of routine chlamydia screening among MSM in care at HIV treatment centers. Our purpose was to elucidate the Dutch situation, wherein routine screening is not currently implemented at these centers. In the transmission model, the MSM population was stratified according to HIV serostatus, presence of chlamydia infection, and sexual risk behavior. In both the transmission and economic model, we studied HIVinfected MSM 'in care' and MSM 'not in care'. The men not in care included those with and without HIV infection.
Eleven parameters describing the course of HIV and chlamydia infection and sexual behavior were included in the uncertainty analysis with a range of possible values (Table 1) [4, 7, . From these ranges, 10 000 sets of values were sampled. From the transmission model we calculated the number of HIV-infected MSM in care with each 10 000 sets of values. Of these sets, we selected the ones that matched the number of HIV-infected MSM in care currently in the Netherlands (N ¼ 8253 in 2011 [32] ), in order to ensure that the results reflected the Dutch situation. This resulted in a selection of 149 parameter sets of the initial 10 000 sets (for details of this selection procedure, see Xiridou et al., submitted). The following data, stratified for MSM not in care and MSM in care, were calculated from the 149 parameter sets and used as input for the economic model: annual number of new cases of HIV, asymptomatic chlamydia, and symptomatic chlamydia; annual number of chlamydia tests among MSM with and without chlamydia symptoms; annual number of detected symptomatic and asymptomatic chlamydia infections. All data were calculated for the whole of the Netherlands over a 20-year period. On the basis of the averages of the above-mentioned annual numbers, we used Excel to calculate the point estimate of the cost-effectiveness of implementing the proposed chlamydia screening program. The transmission model was merged with the economic model, which was programmed in Wolfram Mathematica 8, version 8.0.4.0 (Wolfram Research, Inc., Long Hanborough, UK). This allowed us to calculate the corresponding incremental cost-effectiveness ratio (ICER) of all 149 parameter sets and to illustrate the dispersion. The ICER is defined as the cost difference between new program and current program divided by the difference in quality-adjusted life years (QALYs) between the programs and expressed as euro (s) per QALY gained. Furthermore, we compared these 149 ICERs to all 10 000 ICERs to ensure that we had not created a biased selection with the subtraction of these 149 parameter sets.
Screening strategies
Current situation In the model, all MSM with symptomatic chlamydia are assumed to seek and receive treatment. Additionally, MSM without chlamydia symptoms (those with no chlamydia or asymptomatic chlamydia) may seek screening (i.e. on their own initiative, referred as nonroutine screening) from a GP, dermatologist, or STI clinic. At the HIV treatment centers in the Netherlands, HIV-infected MSM are seen at least twice a year and are typically screened at entry for hepatitis B and hepatitis C and annually for syphilis. Screening for other STI, such as chlamydia and gonorrhea, is currently not part of an HIV consultation at the Dutch HIV treatment centers.
Proposed screening program
In the new program, routine chlamydia screening would be integrated within the scheduled visits of MSM in care at the HIV treatment centers once or twice a year. This routine screening could reduce screening at other healthcare providers, such as STI clinics and GPs. As we do not know how much reduction would occur, we included two different effects. One assumes that, of all HIV-infected MSM in care without chlamydia symptoms, 30% obtain nonroutine screening every year. The 30% is based on the results of a study among MSM in care at HIV treatment centers in the Netherlands, in which 30% reported STI screening in the last 6 months [10] . Of this 30%, we assume that those seeking screening twice-yearly will drop to once-yearly, and those screened once-yearly will stop completely. The second effect we studied is that no HIV-infected MSM will seek screening elsewhere when routine screening is implemented at HIV treatment centers. Thus, the four following scenarios:
(1) All HIV-infected MSM in care will be screened onceyearly at an HIV treatment center for chlamydia, of whom (I) 30% will be screened once-yearly elsewhere, or (II) none will be screened elsewhere. (2) All HIV-infected MSM in care will be screened twiceyearly at an HIV treatment center for chlamydia, of whom (III) 30% will be screened once-yearly elsewhere, or (IV) none will be screened elsewhere.
All four scenarios include the current standard of STI care in the Netherlands; thus, all HIV-infected MSM diagnosed with a chlamydia infection are provided with 'Routine STI screening among HIV-infected MSM' Vriend et al. 2283 As these costs are s0 for MSM consulting an STI clinic, we calculated an average of s7 based on the estimated proportion of STI screening at the STI clinic, GP and dermatology [10] .
h On the basis of an average frequency of consultation of twice a year.
appropriate counseling, partner notification, treatment, testing for chlamydia, and gonorrhea at multiple anatomical locations (i.e. genital, anorectal, and oral) and testing for syphilis.
Costs and health outcomes
We calculated the costs and QALYs for each scenario over a 20-year period. Costs and QALYs were discounted at 4 and 1.5% per year, respectively, according to Dutch guidelines [35] . Acceptability curves were drawn for the four scenarios presenting the percentages of the 149 parameter sets at which the new program is costeffective for a certain willingness-to-pay value for one QALY gained.
The economic model included costs for chlamydia screening at an HIV treatment center, using a nucleic acid amplification test (NAAT), and for treatment of three infections: HIV, symptomatic chlamydia, and asymptomatic chlamydia ( Table 1 ). For HIV-infected MSM in care who tested positive for chlamydia, costs reflected referral to an STI clinic for further testing, treatment, counseling, and partner notification. We assumed a delay in the making of costs for HIV consultation, given the delay between time of HIV infection and diagnosis: 50% were assumed to be diagnosed within 1 year after infection, 30% within 2 years, and 20% within 3 years [36, 37] . We added a delay for the start of costs of HIV treatment with combination antiretroviral drug therapy (cART): 24% of MSM started in the first year after diagnosis, 23% in the second year, 21% in the third year, 11% in the fourth year, 8% in the fifth year, 8% in the sixth year, 4% in the seventh year, and 2% in the eighth year [38] .
We calculated the loss in health-related quality of life (HQoL) weight due to a certain health state (i.e. HIV, asymptomatic chlamydia, symptomatic chlamydia) by subtracting the corresponding HQoL weight from the HQoL weight of the healthy general male population aged 18-65 years ( Table 1) . To estimate the corresponding QALY, these HQoL weights were combined with the duration of time spent in each health state. One-way sensitivity analyses of the costs and HQoL weights were performed for scenario I (i.e. once-yearly screening of MSM at an HIV treatment center, with 30% also being screened once-yearly elsewhere) by adding and subtracting 25% from unit costs and HQoL weights.
Results
Twice-yearly chlamydia screening of MSM in care averted more chlamydia infections among the total MSM population than once-yearly screening, an average of 2179 (11%) and 768 (4%) infections per year over 20 years, respectively, with 30% of MSM in care also being screened nonroutinely once-yearly ( Table 2) . These averages includes averted chlamydia infections among MSM not in care who are not part of the routine screening program, with higher percentages of averted chlamydia infections observed than among MSM in care at an HIV treatment center. Likewise, more HIV infections were averted with twice-yearly screening compared with once-yearly screening, an average of 11 (3%) and four (1%) infections per year over 20 years, respectively, with 30% of MSM also being screened nonroutinely once-yearly (Table 2) . Averted HIV and chlamydia infections per year over 20 years are given in Figure S1 in the Supplemental Digital Content, http:// links.lww.com/QAD/A354. In addition, more QALYs will be gained with twice-yearly screening than with once-yearly screening, but more testing raised the costs of screening MSM in care and treating the new found chlamydia infections ( When comparing the proposed screening program with current practice, three of the four scenarios (i.e., I, II and IV) were cost saving over 20 years ( Table 2 ). The only exception was scenario III, in which MSM are screened twice-yearly at an HIV treatment center, and 30% of them are screened nonroutinely once-yearly (s79 000 per QALY gained). For the three scenarios in which the program was cost saving, most cost were saved among MSM in care and reflects the assumption that a smaller proportion of HIV-infected MSM in care are screened nonroutinely elsewhere when routine chlamydia screening is implemented at HIV treatment centers. The saved costs are due to the lower costs of routine screening compared with nonroutine screening, as chlamydia screening during a routine HIV consultation adds cost only for material, diagnostics, and 5 minutes of nursing time. The largest effect in QALYs, however, is seen in the MSM population outside the HIV treatment centers, for whom a large number of chlamydia infections are averted as well as some HIV infections.
Results of sensitivity analyses
The uncertainty in the ICERs for the four scenarios is depicted in the cost-effectiveness planes (Fig. 1) . The program is cost saving when the incremental costs are below zero; the dots below the horizontal line at zero incremental costs represent a cost-saving program. The dots below the black solid and dashed lines represent the program being cost-effective when the society is willing to pay s20 000 and s50 000 per QALY gained, respectively. The uncertainty of the estimations is higher for a routine screening program with twice-yearly screening (scenarios III and IV), as indicated by the greater dispersion of the dots. The proportion of the black dots (representing the 149 parameter sets) that are cost-effective at a certain willingness to pay threshold are displayed in the cost-effectiveness acceptability curves (Fig. 2) . For example, when the society is willing to pay s20 000 to s50 000 per QALY gained, the probability is 0.77 to 0.83, respectively, that a once-yearly routine program is cost-effective when 30% of MSM are also screened nonroutinely (scenario I). Whereas, with twice-yearly routine screening and 30% of MSM also being screened nonroutinely once-yearly (scenario III), the probability would be 0.26 to 0.37. Only scenario II, with once-yearly routine screening and no nonroutine screening, is 100% cost-effective at these thresholds (i.e. a probability that the program is cost-effective of 1.0 at an ICER threshold of s20 000 to s50 000 per QALY gained).
The dispersion of the dots is caused by the different combinations of parameter values within the transmission model. In the uncertainty analysis, 11 parameters were included that were relevant for the model (Table 1) . Four had a strong influence on the ICER: the probability of HIV transmission per act of UAI; the probability of chlamydia transmission per act of UAI; the number of acts of UAI per year in a casual partnership with multiple sexual acts; the rate of nonroutine screening per year among high-risk HIV-infected MSM in care. Their influence on the ICER (left column Fig. 3 ), costs (middle column Fig. 3 ), and QALYs (right column Fig. 3 ) are given for the scenario of once-yearly routine chlamydia screening with 30% being also screened nonroutinely once-yearly. For example, the first row of Fig. 3 describes the ICER, costs, and QALYs at different probability rates (range 0.003-0.009) of HIV transmission per sex act that were included in the transmission model. At high transmission rates (>0.007), the screening program was cost-effective: all dots lie below the ICER threshold of s20 000 to s50 000 per QALY gained. Whereas, at low transmission rates (<0.006) several dots lie above this ICER threshold, indicating a program that is not cost-effective. Parameter sets including low transmission rates tend to result in higher costs than parameter sets including high transmission rates. In addition, lower transmission rates tend to result in less QALYs gained.
As the other seven uncertain parameters had no visible effect on the ICER, these data are not shown.
Scenario I was also used to evaluate the robustness of the mean cost-effectiveness (see Fig. S3 in the Supplemental Digital Content, http://links.lww.com/QAD/A354). The one-way sensitivity analyses showed that the unit cost for nonroutine STI screening had the largest influence on the incremental costs. When the costs of current nonroutine STI screening would be 25% lower than the base case value (i.e., s152 versus s203, respectively), the program would cost approximately s60 000 per QALY gained instead of saving s70 000 per QALY gained. In contrast, when the costs of current nonroutine STI screening would be 25% higher than the base value, namely s254, the program would save approximately s200 000 per QALY gained. The second most important parameter was the unit cost of routine chlamydia screening at HIV treatment centers. Increasing the base case cost of routine chlamydia screening with 25% would result in a program that cost approximately s8000 per QALY gained, whereas lowering the base case cost of routine chlamydia screening by 25% would make the program more cost saving, approximately s150 000 saved per QALY gained. The HQoL weight for symptomatic chlamydia had the most influence on the QALYs gained, but the program remained cost saving in this sensitivity analysis.
Discussion
Routine chlamydia screening of MSM in care at HIV treatment centers in the Netherlands has the potential to be cost-effective if only a limited proportion of these men seeks nonroutine screening as well. Of our four scenarios, only a twice-yearly screening program combined with nonroutine screening by 30% of MSM in care is not cost-effective over a 20-year period. With routine chlamydia screening and full STI care for chlamydia-infected MSM at HIV treatment centers, nonroutine screening is likely to decline substantially. This decline would more than offset the cost of increased services at HIV centers, as nonroutine screening is considerably more expensive than adding routine screening to a scheduled visit. Fig. 1 . The cost-effectiveness planes of once-yearly or twice-yearly chlamydia screening in MSM in care at HIV treatment centers, assuming that 30 or 0% of them will be screened once a year nonroutinely at other healthcare providers. ICER threshold of s20 000 per QALY gained (solid line) and s50 000 per QALY gained (dashed line) are shown over 20 years, with black dots representing the 149 parameter sets and the grey dots the total 10 000 parameter sets. The dots below the horizontal line at zero incremental costs represent a program that is cost saving. The dots below the black solid line represent the program being costeffective when society is willing to pay s20 000 per QALY gained; the dots below the dashed line represent the program being cost-effective when society is willing to pay s50 000 per QALY gained. ICER, incremental cost-effectiveness ratio; QALY, qualityadjusted life year.
The transmission model found that, in addition to averting large numbers of chlamydia cases in the MSM population, routine screening may also avert some HIV infections. The decline in chlamydia cases is in line with the declining STI incidence seen in the United States on implementation of routine STI screening among MSM in care at HIV treatment centers [3] . The effect of chlamydia on HIV cases is in line with hypotheses that STI in an HIV-infected person may increase HIV transmissibility and that STI in an HIV-uninfected person may increase susceptibility to HIV infection [4] [5] [6] [7] [8] . This interaction between chlamydia and HIV was included in the transmission model. However, it was assumed that the impact of chlamydia on HIV transmission was small, as HIV infectivity is already diminished in individuals with undetectable viral load [19, 39] . In industrialized countries, most of the HIV-infected MSM in care receive cART; thus, persons with an undetectable viral load comprise the majority of the target group for the proposed screening program.
Some studies suggest that routine STI screening at HIV treatment centers would have a high impact on HIV incidence, with high cost saving due to much lower HIV treatment costs, which alone could make STI screening cost-effective [40, 41] . However, our economic analyses showed that the estimated costs saved due to averted HIV and chlamydia cases were not large enough to offset the costs of the new screening program. A possible future drop in the price of HIV medication will likewise have very limited effect on the outcomes of this economic model. The program would only be costeffective if accompanied by a decline in the proportion of MSM that additionally are screened by other healthcare providers. Integrating STI and HIV care would strengthen the cost-effectiveness of the program, offering full STI screening and HIV care at one site on a regular basis, making it unnecessary to screen elsewhere.
The feasibility of such integration could be explored in countries wherein HIV treatment centers do not yet offer a complete STI consultation during HIV visits.
The current study has some limitations. Constructing a transmission model that describes HIV and chlamydia transmission, including the effect on HIV transmission of chlamydia in HIV-infected MSM, is dependent on the availability of robust data. Although we made strong efforts to identify reliable data, some assumptions remain uncertain. However, sensitivity analyses showed that only a few parameters influenced the final ICERs, and that they remained below s0 per QALY gained for the majority of the assumed values in scenario I (once-yearly routine screening with 30% of patients also receiving once-yearly screening elsewhere). The assumption that 30% of all HIV-infected MSM in care, without chlamydia symptoms, will be screened nonroutinely once a year could be an overestimation. In any case, we assumed that MSM now seeking twice-yearly screening would reduce such screening to once-yearly if routine screening were implemented. We estimated this group to be 30% of the HIV-infected MSM population based on a questionnaire from another study [10] that only asked about STI screening in the last 6 months and did not ask whether it was random screening or one regularly sought every 6 months. Another limitation is that this analysis did not consider the cost-effectiveness of routine screening for chlamydia at multiple anatomical test sites or the addition of screening for other STI coinfections, like gonorrhea. As gonorrhea and chlamydia can be tested with the same NAAT, screening for anorectal gonorrhea could quite easily be combined with screening for anorectal chlamydia. However, it is unknown what effect the addition of gonorrhea to the screening program would have on the outcomes of the transmission and the economic models.
We are not aware of any other study investigating the cost-effectiveness of routine chlamydia screening in the population of HIV-infected MSM that also includes the effect of screening on transmission of both HIV and chlamydia. Modeling studies in the United States have investigated the cost-effectiveness of STI screening and its effect on HIV incidence, but they focused on transmission in heterosexuals, did not take into account the effect of cART, and included asymptomatic as well as symptomatic STI [40, 41] .
In conclusion, routine chlamydia screening and treatment of MSM in care at HIV treatment centers will avert a large number of chlamydia infections as well as some HIV infections in the general MSM population. The cost-effectiveness of such a program pivots on the amount saved by reducing nonroutine consultation elsewhere, which is considerably more expensive than adding routine chlamydia screening to a scheduled visit. If STI and HIV care are fully integrated, there should be very limited need for nonroutine screening. Thus, a onceyearly or even twice-yearly program that combines STI screening and HIV care at one site is an effective and potentially cost-saving program. Costs (millions €) Fig. 3 . The influence of different values of four parameters, which were uncertain in the transmission model, on the individual ICERs, incremental costs, and QALYs (left, middle, and right column, respectively) with once-yearly chlamydia screening of MSM at the HIV treatment center, of whom 30% will be screened once a year nonroutinely elsewhere (scenario I). ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; UAI, unprotected anal intercourse.
